{"schema_version":"1","generated_at":"2026-11-02T08:19:46.428Z","data_as_of":null,"url":"https://www.findmykol.com/kol/michael-rosenzweig","json_url":"https://www.findmykol.com/kol/michael-rosenzweig/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"michael-rosenzweig","name":"Michael Rosenzweig","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"City Of Hope National Medical Center","institution_url":"https://www.findmykol.com/institution/city-of-hope","city":"Duarte","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1164470126","orcid":"0000-0001-5158-5131","openalex":"A5024461673"},"summary":"Michael Rosenzweig is an Oncology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 164 publications with 8,256 citations (h-index 41); ClinicalTrials.gov lists 5 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":164,"cited_by_count":8256,"h_index":41,"latest_activity_year":2025,"source":"works"},"trials":{"count":5,"shown":3,"withheld":4,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05014646","title":"Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"City of Hope Medical Center","source_url":"https://clinicaltrials.gov/study/NCT05014646","trial_url":"https://www.findmykol.com/trial/NCT05014646"},{"nct":"NCT04847453","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","phase":"PHASE1","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT04847453","trial_url":"https://www.findmykol.com/trial/NCT04847453"},{"nct":"NCT04508790","title":"Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"City of Hope Medical Center","source_url":"https://clinicaltrials.gov/study/NCT04508790","trial_url":"https://www.findmykol.com/trial/NCT04508790"}],"source":"trials"},"payments":{"company_count":10,"program_years":{"first":2021,"last":null},"rows_total":21,"shown":3,"withheld":18,"rows":[{"payer":"Janssen Research & Development, LLC","program_year":2025,"amount_usd":870,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1164470126"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":629.6,"payment_count":12,"source_url":"https://openpaymentsdata.cms.gov/search?query=1164470126"},{"payer":"Celgene Corporation","program_year":2025,"amount_usd":156.25,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1164470126"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1164470126","source":"payments"},"prescribing":{"data_year":2024,"areas_total":6,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":66.7,"classes_total":2,"classes":[{"class":"Thalidomide Analog","setting":"prescribed","share_pct":63.5,"drugs":[{"name":"Revlimid","share_pct":63.7},{"name":"Pomalyst","share_pct":20.5},{"name":"Lenalidomide","share_pct":15.8}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":3.2,"drugs":[{"name":"Brukinsa","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":11.9,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":11.9,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":17}]},{"area":"Nervous system","share_pct":10.8,"classes_total":2,"classes":[{"class":"Other nervous system drugs","setting":"prescribed","share_pct":7.6,"drugs":[{"name":"Vyndamax","share_pct":100}],"max_beneficiaries":null},{"class":"Gabapentinoids","setting":"prescribed","share_pct":3.2,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":27.1,"facility_pct":72.9},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2021,"last":2025},"rows_total":4,"shown":3,"withheld":1,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R01CA253545","title":"Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans","fiscal_year":2025,"amount_usd":"677645","organization":"BECKMAN RESEARCH INSTITUTE/CITY OF HOPE","source_url":"https://reporter.nih.gov/quickSearch/R01CA253545"},{"project":"R01CA253545","title":"Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans","fiscal_year":2023,"amount_usd":"653591","organization":"BECKMAN RESEARCH INSTITUTE/CITY OF HOPE","source_url":"https://reporter.nih.gov/quickSearch/R01CA253545"},{"project":"R01CA253545","title":"Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans","fiscal_year":2022,"amount_usd":"656771","organization":"BECKMAN RESEARCH INSTITUTE/CITY OF HOPE","source_url":"https://reporter.nih.gov/quickSearch/R01CA253545"}],"source":"grants"},"contact":{"address_1":"1500 DUARTE RD","city":"Duarte","state":"CA","zip":"910103012","phone":"626-256-4673","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1164470126","source":"identity"},"similar":[{"name":"Erminia Massarelli","slug":"erminia-massarelli","institution":"City Of Hope National Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/erminia-massarelli","json_url":"https://www.findmykol.com/kol/erminia-massarelli/profile.json"},{"name":"Swetha Thiruvengadam","slug":"swetha-thiruvengadam","institution":"City Of Hope National Medical Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/swetha-thiruvengadam","json_url":"https://www.findmykol.com/kol/swetha-thiruvengadam/profile.json"},{"name":"Yuman Fong","slug":"yuman-fong","institution":"City Of Hope National Medical Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/yuman-fong","json_url":"https://www.findmykol.com/kol/yuman-fong/profile.json"},{"name":"Ravi Salgia","slug":"ravi-salgia","institution":"City Of Hope National Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ravi-salgia","json_url":"https://www.findmykol.com/kol/ravi-salgia/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":4,"payments":18,"funding":1}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2015-08-17","collected_at":"2026-11-02T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}